Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report

Abstract

This case report describes the first successful treatment of alopecia areata and atopic dermatitis with the Janus kinase 1 inhibitor upadacitinib in a paediatric patient. After minimal response to topical corticosteroids and spironolactone, improvements in hair growth on the scalp and body were noted after only 6 weeks of upadacitinib treatment.

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

“…18 Based on this review, we have summarized the latest reports of JAK inhibitor treatment for pediatric AA in the past 2 years (Table 1). 18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years.…”

“…18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years. 36 Selective JAK1 inhibitors have potential safety advantages because of their specific pathway targeting, offering greater JAK2-related hematopoietic function preservation than non-selective inhibitors.…”

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment

“…Strong topical glucocorticosteroids (clobetasol propionate) are used preferentially, occasionally under occlusion. Some dermatologists use contact immunotherapy [9]. Bimatoprost may help regrow eyebrows in alopecia areata.…”

“…Stosowane są przede wszystkim bardzo silne glikokortykosteroidy miejscowo (propionian klobetazolu), niekiedy pod okluzję. W niektórych ośrodkach stosuje się immunoterapię kontaktową [9]. Bimatoprost może wspomagać odrost brwi w łysieniu plackowatym.…”

Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata

“…Upadacitinib is a selective JAK-1 inhibitor initially approved for the treatment of rheumatoid arthritis and recently further expanded to treat Psoriatic Arthritis (PsA), ankylosing spondylitis, ulcerative colitis and AD [3]. Upadacitinib has been reported in few case studies for the treatment of AA however, it has not been indicated for treatment of plaque PsO [4,5]. We present a patient with AD, PsO, PsA and AA refractory to multiple agents however, successfully treated with upadacitinib.…”